HBV Treatment With Approved Agents: Data From AASLD 2008

[Guest guest]

CCO is an independent medical education company that provides state-of-the-art

medical information to

healthcare professionals through conference coverage and other educational

programs.

Official Online Conference Coverage*

Click to Access

Advances in HBV Treatment With Approved Agents:

Data From AASLD 2008

*CCO is the official provider of online conference coverage of the

2008 Meeting of the American Association for the Study of Liver Diseases (AASLD)

October 31 - November 4, 2008 | San Francisco, California

Watch and listen to experts review the most important data from San Francisco,

California

in downloadable video and audio formats.

browse available Expert Highlights or choose a topic below to access the format

most convenient for you.

Click to Access

Approved HBV Agents

G. Gish, MD, reviews data from AASLD 2008 on frontline hepatitis B

treatment options with approved agents and predicting response based on patient

and viral characteristics.

To access this Expert Highlight, click here.

This Expert Highlight is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202008.aspx

Advances in HBV Treatment With Approved Agents — Click a link below to access a

Capsule Summary

Treatment With Tenofovir for 96 Weeks Results in High Rate of HBV DNA

Suppression in Patients With HBeAg-Negative Chronic HBV Infection

Tenofovir Provides Effective and Sustained Virologic Suppression in

HBeAg-Positive HBV-Infected Patients Through 96 Weeks

Low Rate of HBV Recurrence When Antiviral Therapy and HBIG Given Together as

Prophylaxis After Liver Transplantation

Predictors of HBsAg Loss in HBeAg-Negative Patients Following Long-term Adefovir

Treatment Identified

Rituximab Administration Associated With Reactivation of Hepatitis B

Higher Rates of Virologic Suppression With 6 Months of Entecavir vs Adefovir or

Adefovir Plus Lamivudine Treatment in Lamivudine-Resistant Patients Awaiting OLT

Long-term Entecavir Treatment Results in Durable HBV Suppression in

Treatment-Naive, HBeAg-Positive Patients

Clinical Experience in Italy Confirms Efficacy and Low Resistance Rates With

Entecavir in Nucleos(t)ide-Naive Patients With Chronic Hepatitis B

Week 12 On-Treatment HBsAg Level Predicts Long-term Posttreatment Virologic

Response in Patients With HBeAg-Negative Chronic Hepatitis B Infection Treated

With Peginterferon alfa-2a ± Lamivudine

Small Retrospective Study Finds Switching to Tenofovir Possibly a Viable Option

for HBV-Infected Patients With Suboptimal Response to Entecavir

Liver Fibrosis and Cirrhosis Present in Many Non-Asian Patients With Chronic HBV

Infection and Normal or Moderately Elevated ALT Levels

Peginterferon alfa-2a Response Rates in HBeAg-Positive Korean Patients With

Lamivudine Resistance Similar to Lamivudine-Naive Patients

Entecavir Combined With Tenofovir Effective and Well Tolerated in Cirrhotic

HBV-Infected Patients With Multidrug-Resistant HBV

These Capsule Summaries are located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202008.aspx

Coming soon: CME/CE-certified Expert Analyses

Physicians:

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care

Options, LLC.

Nurses:

Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:

Postgraduate Institute for Medicine is accredited by the Accreditation Council

for Pharmacy Education as a provider of continuing pharmacy education. Pharmacy

credit hours provided through the cosponsorship of Postgraduate Institute for

Medicine and Clinical Care Options, LLC.

Supported by educational grants from Bristol-Myers Squibb; Gilead Sciences;

Merck; Pharmasset, Inc.; and Vertex.

CCO is the official provider of online conference coverage of The Liver Meeting®

2008.

http://www.aasld.org

CCO Hepatitis | RSS | Hepatitis Podcasts | Bookstore | Slideset Downloads

To ensure you receive Clinical Care Options educational materials by email,

please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

Not a member yet? Click here | Unsubscribe from all emails sent from CCO |

Manage email preferences

[Guest guest]

CCO is an independent medical education company that provides state-of-the-art

medical information to

healthcare professionals through conference coverage and other educational

programs.

Official Online Conference Coverage*

Click to Access

Advances in HBV Treatment With Approved Agents:

Data From AASLD 2008

*CCO is the official provider of online conference coverage of the

2008 Meeting of the American Association for the Study of Liver Diseases (AASLD)

October 31 - November 4, 2008 | San Francisco, California

Watch and listen to experts review the most important data from San Francisco,

California

in downloadable video and audio formats.

browse available Expert Highlights or choose a topic below to access the format

most convenient for you.

Click to Access

Approved HBV Agents

G. Gish, MD, reviews data from AASLD 2008 on frontline hepatitis B

treatment options with approved agents and predicting response based on patient

and viral characteristics.

To access this Expert Highlight, click here.

This Expert Highlight is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202008.aspx

Advances in HBV Treatment With Approved Agents — Click a link below to access a

Capsule Summary

Treatment With Tenofovir for 96 Weeks Results in High Rate of HBV DNA

Suppression in Patients With HBeAg-Negative Chronic HBV Infection

Tenofovir Provides Effective and Sustained Virologic Suppression in

HBeAg-Positive HBV-Infected Patients Through 96 Weeks

Low Rate of HBV Recurrence When Antiviral Therapy and HBIG Given Together as

Prophylaxis After Liver Transplantation

Predictors of HBsAg Loss in HBeAg-Negative Patients Following Long-term Adefovir

Treatment Identified

Rituximab Administration Associated With Reactivation of Hepatitis B

Higher Rates of Virologic Suppression With 6 Months of Entecavir vs Adefovir or

Adefovir Plus Lamivudine Treatment in Lamivudine-Resistant Patients Awaiting OLT

Long-term Entecavir Treatment Results in Durable HBV Suppression in

Treatment-Naive, HBeAg-Positive Patients

Clinical Experience in Italy Confirms Efficacy and Low Resistance Rates With

Entecavir in Nucleos(t)ide-Naive Patients With Chronic Hepatitis B

Week 12 On-Treatment HBsAg Level Predicts Long-term Posttreatment Virologic

Response in Patients With HBeAg-Negative Chronic Hepatitis B Infection Treated

With Peginterferon alfa-2a ± Lamivudine

Small Retrospective Study Finds Switching to Tenofovir Possibly a Viable Option

for HBV-Infected Patients With Suboptimal Response to Entecavir

Liver Fibrosis and Cirrhosis Present in Many Non-Asian Patients With Chronic HBV

Infection and Normal or Moderately Elevated ALT Levels

Peginterferon alfa-2a Response Rates in HBeAg-Positive Korean Patients With

Lamivudine Resistance Similar to Lamivudine-Naive Patients

Entecavir Combined With Tenofovir Effective and Well Tolerated in Cirrhotic

HBV-Infected Patients With Multidrug-Resistant HBV

These Capsule Summaries are located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202008.aspx

Coming soon: CME/CE-certified Expert Analyses

Physicians:

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care

Options, LLC.

Nurses:

Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute

for Medicine is accredited as a provider of continuing nursing education by the

American Nurses Credentialing Center's Commission on Accreditation.

Pharmacists:

Postgraduate Institute for Medicine is accredited by the Accreditation Council

for Pharmacy Education as a provider of continuing pharmacy education. Pharmacy

credit hours provided through the cosponsorship of Postgraduate Institute for

Medicine and Clinical Care Options, LLC.

Supported by educational grants from Bristol-Myers Squibb; Gilead Sciences;

Merck; Pharmasset, Inc.; and Vertex.

CCO is the official provider of online conference coverage of The Liver Meeting®

2008.

http://www.aasld.org

CCO Hepatitis | RSS | Hepatitis Podcasts | Bookstore | Slideset Downloads

To ensure you receive Clinical Care Options educational materials by email,

please add info@... to your contacts or address book.

Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

Not a member yet? Click here | Unsubscribe from all emails sent from CCO |

Manage email preferences